Perifosine: Oncolytic ether phospholipid

Drugs of the Future

Volumn 25, Issue 12, 2000, Pages 1257-1260

  Engel, J ^a   Hilgard, P ^a   Klenner, T ^a   Kutscher, B ^a   Nossner G ^a   Traiser, M ^a   Voss, V ^a  

^a ASTA MEDICA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALIZAPRIDE; ANTIEMETIC AGENT; DEXAMETHASONE; ETHER PHOSPHOLIPID; GAMMA INTERFERON; INTERLEUKIN 1BETA; MILTEFOSINE; PERIFOSINE; PHOSPHORYLCHOLINE; TROPISETRON; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BONE MARROW TOXICITY; BREAST CANCER; CANCER; CHEMICAL ANALYSIS; CHEMICAL REACTION; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MOUSE; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RAT; SQUAMOUS CELL CARCINOMA; SYNTHESIS; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE; TUMOR XENOGRAFT; VOMITING;

EID: 0034479244     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.12.604732     Document Type: Article

References (21)

1. Synthesis of hexadecylphosphocholine (miltefosine). Alkylphosphocholines: New drugs in cancer therapy
2. Phase I study with weekly oral miltefosine (hexadecylphosphocholine) in cancer patients
3. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours
4. Phase I study with daily hexadecylphosphocholine in patients with malignant disease
5. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis
6. Leishmaniasis
7. Overview on the clinical development of miltefosine solution (Miltex) for the treatment of cutaneous breast cancer
8. Inhibitors of signal transduction: The alkylphosphocholines
9. Inhibition of phospholipase C and protein kinase C by alkylphosphocholines
10. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis
11. Interference of new alkylphospholipid analogues with mitogenic signal transduction
12. D-21266, a new heterocyclic alkylphospholipid with antitumour activity
13. Loading-dose/maintenance dose schedule increases the therapeutic efficacy of D-21266, a new alkylphosphocholine
14. Activation of caspase 3-like protease is essential to octadecyl-(1,1-dimethyl-4-piperidino-4-yl)-phosphate (D-21266)-induced apoptosis in human squamous cell carcinoma KB cells
15. Alkylphosphocholines induce programmed cell death in bladder cancer cell lines
16. Morphological changes and cytokine gene expression in tumor xenografts following treatment with the alkylphosphocholines hexadecylphosphocholine and perifosine
17. Quantification of perifosine, an alkylphosphocholine anti-tumour agent, in plasma by pneumatically assisted electrospray tandem mass spectrometry coupled with high-performance liquid chromatography
18. Phase I study with weekly oral perifosine (D-21266) in patients with advanced cancer
19. Clinical and pharmacokinetic phase I evaluation of the second generation alkylphosphocholine D-21266 in patients with solid tumor administered once weekly per os
20. Current development status of the second generation alkylphosphocholine analog perifosine
21. Phase I study of perifosine (D-21266), a new alkylphosphocholine analogue